aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Felix Biotech: Accelerating novel biotherapeutics for infectious disease management.
Felix Biotechnology, founded with a mission to combat antimicrobial resistance, is pioneering the development of programmable therapies. The company focuses on creating an end-to-end digital viral design platform aimed at revolutionizing infectious disease management. By leveraging advanced biotechnology, Felix Biotech aims to provide innovative biotherapeutics that address the growing threat of drug-resistant infections.
Notable figures associated with Felix Biotechnology include experts in virology and biotech innovation, although specific names are not disclosed. The company has garnered attention from investors interested in cutting-edge healthcare solutions. Key achievements include the development of their digital viral design platform, which has the potential to significantly impact global health by offering new treatments for resistant infections. Felix Biotech's work represents a critical advancement in the fight against antimicrobial resistance, positioning them as a leader in the field of biotherapeutics.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Biotherapeutics
Technology
Biotech
Tags
Biotech
Model Types
Platform
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Felix Biotechnology founded?
Felix Biotechnology was founded in 2019.
Where is Felix Biotechnology’s headquarters located?
Felix Biotechnology’s headquarters is located in San Francisco, CA, US.
When was Felix Biotechnology’s last funding round?
Felix Biotechnology’s most recent funding round was for $314.4k (USD) in July 2022.
How many employees does Felix Biotechnology have?
Felix Biotechnology has 6 employees as of Apr 17, 2024.
How much has Felix Biotechnology raised to-date?
As of July 05, 2023, Felix Biotechnology has raised a total of $720.4k (USD) since Jul 14, 2022.
Add Comparison
Total Raised to Date
$720.4k
USD
Last Update Jul 14, 2022
Last Deal Details
$314.4k
USD
Jul 14, 2022
Grant
Total Employees Over Time
6
As of Apr 2024
Felix Biotechnology Address
San Francisco,
California
94115
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts